Emmaus生命科学授予Nit公司Endari在美国及加拿大的独家营销权

美股速递
Dec 31, 2025

Emmaus生命科学公司已正式签署协议,将其创新药物Endari在美国与加拿大地区的独家市场推广、销售及分销权利授予Nit公司。

此次授权合作将显著拓展Endari在北美市场的可及性,为当地患者提供这一重要治疗选择。双方将协同推进该药物的商业化进程,深化在罕见病治疗领域的战略布局。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10